$NKTR
NEKTAR THERAPEUTICS

2013 Form 10-K Financial Statement

#000119312514073093 Filed on February 27, 2014

View on sec.gov

Income Statement

Concept 2013 2012 Q4 2012 Q3
Revenue $148.9M $21.15M $18.41M
YoY Change 83.42% 33.99% -31.98%
Cost Of Revenue $38.51M $7.290M $7.228M
YoY Change 26.56% 33.76% 43.47%
Gross Profit $110.4M $13.86M $11.18M
YoY Change 117.5% 34.11% -49.23%
Gross Profit Margin 74.14% 65.53% 60.74%
Selling, General & Admin $40.50M $10.90M $10.10M
YoY Change -2.64% -5.22% -18.55%
% of Gross Profit 36.68% 78.67% 90.31%
Research & Development $190.0M $46.37M $34.02M
YoY Change 27.8% 39.25% 9.67%
% of Gross Profit 172.09% 334.68% 304.15%
Depreciation & Amortization $13.00M $3.900M $3.600M
YoY Change -5.8% 8.33% -5.26%
% of Gross Profit 11.77% 28.15% 32.19%
Operating Expenses $190.0M $46.37M $34.02M
YoY Change 27.8% 39.25% 9.67%
Operating Profit -$120.1M -$43.38M -$32.90M
YoY Change -14.92% 25.86% 54.19%
Interest Expense $18.45M -$9.600M $5.697M
YoY Change 19.14% 317.39% 124.03%
% of Operating Profit
Other Income/Expense, Net -$39.64M -$10.43M
YoY Change 31.04% 295.19%
Pretax Income -$161.1M -$53.00M -$43.33M
YoY Change -7.57% 44.02% 80.7%
Income Tax $2.245M $0.00 $222.0K
% Of Pretax Income
Net Earnings -$162.0M -$52.93M -$43.55M
YoY Change -5.73% 41.15% 80.93%
Net Earnings / Revenue -108.79% -250.29% -236.51%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.400M -$459.2K -$378.6K
COMMON SHARES
Basic Shares Outstanding 115.2M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 2012 Q4 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $237.0M $277.2M $319.3M
YoY Change -14.5% 14.93% 19.81%
Cash & Equivalents $39.10M $25.44M $10.34M
Short-Term Investments $198.0M $251.8M $308.9M
Other Short-Term Assets $5.200M $13.36M $7.003M
YoY Change -61.19% -25.53% -7.86%
Inventory $13.50M $18.27M $16.75M
Prepaid Expenses
Receivables $2.200M $5.805M $3.911M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $257.9M $314.6M $346.9M
YoY Change -18.02% 13.71% 16.58%
LONG-TERM ASSETS
Property, Plant & Equipment $67.00M $72.22M $73.26M
YoY Change -7.2% -8.1% -10.23%
Goodwill $76.50M $76.50M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments $0.00 $35.00M
YoY Change -100.0% -81.72%
Other Assets $33.20M $9.443M $9.728M
YoY Change -3.49% 845.25% 1116.0%
Total Long-Term Assets $176.6M $183.2M $194.5M
YoY Change -3.6% -44.47% -44.51%
TOTAL ASSETS
Total Short-Term Assets $257.9M $314.6M $346.9M
Total Long-Term Assets $176.6M $183.2M $194.5M
Total Assets $434.5M $497.8M $541.5M
YoY Change -12.72% -17.93% -16.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.100M $2.863M $2.624M
YoY Change 213.79% -5.17% 19.27%
Accrued Expenses $44.30M $8.008M $6.450M
YoY Change 7.0% 20.08% -82.61%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $98.20M $78.54M $69.47M
YoY Change 25.1% -71.5% -75.1%
LONG-TERM LIABILITIES
Long-Term Debt $203.0M $136.6M $264.2M
YoY Change 48.61% 835.62% 1626.8%
Other Long-Term Liabilities $223.2M $10.81M $10.73M
YoY Change -5.26% 51.01% -91.28%
Total Long-Term Liabilities $426.2M $10.81M $10.73M
YoY Change 14.51% 51.01% -92.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $98.20M $78.54M $69.47M
Total Long-Term Liabilities $426.2M $10.81M $10.73M
Total Liabilities $524.4M $450.8M $446.1M
YoY Change 16.33% 10.28% 6.91%
SHAREHOLDERS EQUITY
Retained Earnings -$1.570B -$1.517B
YoY Change 12.29%
Common Stock $1.618B $1.613B
YoY Change 1.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$89.90M $47.02M $95.33M
YoY Change
Total Liabilities & Shareholders Equity $434.5M $497.8M $541.5M
YoY Change -12.72% -17.93% -16.46%

Cashflow Statement

Concept 2013 2012 Q4 2012 Q3
OPERATING ACTIVITIES
Net Income -$162.0M -$52.93M -$43.55M
YoY Change -5.73% 41.15% 80.93%
Depreciation, Depletion And Amortization $13.00M $3.900M $3.600M
YoY Change -5.8% 8.33% -5.26%
Cash From Operating Activities -$38.53M -$47.40M -$27.20M
YoY Change -70.31% 12.32% 24.77%
INVESTING ACTIVITIES
Capital Expenditures $4.091M -$4.900M -$2.500M
YoY Change -61.34% 250.0% 66.67%
Acquisitions
YoY Change
Other Investing Activities $54.00M $67.10M -$2.900M
YoY Change -56.31% 322.01% -105.36%
Cash From Investing Activities $49.91M $62.20M -$5.400M
YoY Change -55.84% 331.94% -110.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.216M 200.0K -93.20M
YoY Change -91.73% -166.67%
NET CHANGE
Cash From Operating Activities -38.53M -47.40M -27.20M
Cash From Investing Activities 49.91M 62.20M -5.400M
Cash From Financing Activities 2.216M 200.0K -93.20M
Net Change In Cash 13.60M 15.00M -125.8M
YoY Change 35.1% -153.38% -507.12%
FREE CASH FLOW
Cash From Operating Activities -$38.53M -$47.40M -$27.20M
Capital Expenditures $4.091M -$4.900M -$2.500M
Free Cash Flow -$42.62M -$42.50M -$24.70M
YoY Change -69.63% 4.17% 21.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
126766000
CY2011Q4 nktr Additional Area Included In Operating Sublease After Amendment
AdditionalAreaIncludedInOperatingSubleaseAfterAmendment
24002 sqft
CY2014Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
126645285 shares
CY2012Q3 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
25000000
CY2012Q3 nktr Convertible Subordinated Notes Remaining
ConvertibleSubordinatedNotesRemaining
172400000
CY2013Q2 dei Entity Public Float
EntityPublicFloat
1330867461
CY2010Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
13058000
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
90662000
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17755000
CY2011Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
13576000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
197811000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15312000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
115259000 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
115259000 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8008000
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
72666000
CY2012Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2863000
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
534268000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
78537000
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-357000
CY2012Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
125000000
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
14067000
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8773000
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
10811000
CY2012Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
11607000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
47018000
CY2011 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-943000
CY2013 us-gaap Deferred Compensation Arrangement With Individual Employer Contribution
DeferredCompensationArrangementWithIndividualEmployerContribution
3000
CY2011 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
4530000
CY2011 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2245000
CY2011 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
CY2011 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
922000
CY2011 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
12267000
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1617744000
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
CY2012Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1570380000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
21896000
CY2012Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
497790000
CY2012Q4 us-gaap Liabilities
Liabilities
450772000
CY2012Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
9414000
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
96551000
CY2012Q4 us-gaap Interest Payable Current
InterestPayableCurrent
7083000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
25000000
CY2012Q4 us-gaap Capital Leases Balance Sheet Assets By Major Class Net
CapitalLeasesBalanceSheetAssetsByMajorClassNet
1400000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
314631000
CY2012Q4 us-gaap Goodwill
Goodwill
76501000
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
23746000
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9443000
CY2012Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
251757000
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
351354000
CY2012Q4 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
2300000
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
534363000
CY2012Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
6661000
CY2012Q4 us-gaap Assets
Assets
497790000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25437000
CY2012Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
7489000
CY2012Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
95000
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5805000
CY2012Q4 us-gaap Inventory Net
InventoryNet
18269000
CY2012Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
95000
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
52769000
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
8776000
CY2012Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
39521000
CY2012Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
252760000
CY2012Q4 us-gaap Other Assets Current
OtherAssetsCurrent
13363000
CY2012Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
2765000
CY2012Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2773000
CY2012Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
4119000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
72215000
CY2012Q4 nktr Number Of Customers Accounted For Major Accounts Receivable
NumberOfCustomersAccountedForMajorAccountsReceivable
4 Customer
CY2012Q4 nktr Depreciable Property Plant And Equipment Net
DepreciablePropertyPlantAndEquipmentNet
69450000
CY2012Q4 nktr Liability Related To Sale Of Potential Future Royalties Non Current
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
128266000
CY2012Q4 nktr Letters Of Credit Outstanding
LettersOfCreditOutstanding
2400000
CY2012Q4 nktr Deferred Tax Assets From Sale Of Future Royalties
DeferredTaxAssetsFromSaleOfFutureRoyalties
39750000
CY2012Q4 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0 shares
CY2012Q4 nktr Cash And Restricted Cash
CashAndRestrictedCash
26947000
CY2012Q4 nktr Liability Related To Sale Of Potential Future Royalties
LiabilityRelatedToSaleOfPotentialFutureRoyalties
131266000
CY2012Q4 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
302194000
CY2012Q4 nktr Depreciable Property Plant And Equipment Gross
DepreciablePropertyPlantAndEquipmentGross
142116000
CY2012Q4 nktr Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
17500000
CY2012Q4 nktr Liability Related To Sale Of Potential Future Royalties Current
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesCurrent
3000000
CY2012Q4 nktr Deferred Tax Assets Capitalized Research Expenses
DeferredTaxAssetsCapitalizedResearchExpenses
7192000
CY2012Q4 nktr Deferred Tax Assets Depreciation Property And Equipment
DeferredTaxAssetsDepreciationPropertyAndEquipment
8482000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
116494000 shares
CY2013Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.12 pure
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
116494000 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
9.06
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6243000
CY2013Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
3536000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
4750000
CY2013Q4 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
12600000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
84148000
CY2013Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
5169000
CY2013Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
28221000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9115000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
5037000
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
586040000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
98221000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1181000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
5796000
CY2013Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
125000000
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
16363000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14254000
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
19256000
CY2013Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
8049000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-89903000
CY2013Q4 us-gaap Liabilities
Liabilities
524430000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1643660000
CY2013Q4 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
160800000
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
CY2013Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2013Q4 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
4034000
CY2013Q4 us-gaap Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
1700000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
5187000
CY2013Q4 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
11585000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1732393000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
23664000
CY2013Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
434527000
CY2013Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
5280000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
4892000
CY2013Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
14123000
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
82384000
CY2013Q4 us-gaap Interest Payable Current
InterestPayableCurrent
6917000
CY2013Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
14483000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2559000
CY2013Q4 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
25000000
CY2013Q4 us-gaap Capital Leases Balance Sheet Assets By Major Class Net
CapitalLeasesBalanceSheetAssetsByMajorClassNet
1000000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
257882000
CY2013Q4 us-gaap Goodwill
Goodwill
76501000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
25962000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8170000
CY2013Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
197959000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
391385000
CY2013Q4 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
2300000
CY2013Q4 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
2898000
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
586190000
CY2013Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
6146000
CY2013Q4 us-gaap Assets
Assets
434527000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39067000
CY2013Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
3947000
CY2013Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
150000
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2229000
CY2013Q4 us-gaap Inventory Net
InventoryNet
13452000
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
150000
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
61707000
CY2013Q4 us-gaap Capital Leases Future Minimum Sublease Rentals
CapitalLeasesFutureMinimumSubleaseRentals
7400000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
14685000
CY2013Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
35588000
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
197959000
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5175000
CY2013Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
23400000
CY2013Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
6261000
CY2013Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2539000
CY2013Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
3359000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
66974000
CY2013Q4 nktr Number Of Customers Accounted For Major Accounts Receivable
NumberOfCustomersAccountedForMajorAccountsReceivable
3 Customer
CY2013Q4 nktr Depreciable Property Plant And Equipment Net
DepreciablePropertyPlantAndEquipmentNet
60713000
CY2013Q4 nktr Debt Instrument Maturity Month And Year
DebtInstrumentMaturityMonthAndYear
2017-07
CY2013Q4 nktr Number Of Securities Available For Issuance Under Equity Compensation Plans
NumberOfSecuritiesAvailableForIssuanceUnderEquityCompensationPlans
7954000 shares
CY2013Q4 nktr Liability Related To Sale Of Potential Future Royalties Non Current
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
121520000
CY2013Q4 nktr Letters Of Credit Outstanding
LettersOfCreditOutstanding
2400000
CY2013Q4 nktr Deferred Tax Assets From Sale Of Future Royalties
DeferredTaxAssetsFromSaleOfFutureRoyalties
28057000
CY2013Q4 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0 shares
CY2013Q4 nktr Cash And Restricted Cash
CashAndRestrictedCash
37614000
CY2013Q4 nktr Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Outstanding
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstanding
20655000 shares
CY2013Q4 nktr Cash And Cash Equivalents Including Restricted Cash
CashAndCashEquivalentsIncludingRestrictedCash
262000000
CY2013Q4 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
262026000
CY2013Q4 nktr Restricted Stock Units Outstanding
RestrictedStockUnitsOutstanding
0 shares
CY2013Q4 nktr Depreciable Property Plant And Equipment Gross
DepreciablePropertyPlantAndEquipmentGross
144861000
CY2013Q4 nktr Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
16905000
CY2013Q4 nktr Liability Related To Sale Of Future Royalties Current And Noncurrent
LiabilityRelatedToSaleOfFutureRoyaltiesCurrentAndNoncurrent
128520000
CY2013Q4 nktr Liability Related To Sale Of Potential Future Royalties Current
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesCurrent
7000000
CY2013Q4 nktr Deferred Tax Assets Capitalized Research Expenses
DeferredTaxAssetsCapitalizedResearchExpenses
17687000
CY2013Q4 nktr Deferred Tax Assets Depreciation Property And Equipment
DeferredTaxAssetsDepreciationPropertyAndEquipment
8580000
CY2013Q4 nktr Refundable Milestone Payment Liabilities
RefundableMilestonePaymentLiabilities
70000000
CY2013Q4 nktr Litigation Settlement Payments
LitigationSettlementPayments
12000000
CY2010 us-gaap Impaired Assets To Be Disposed Of By Method Other Than Sale Amount Of Impairment Loss
ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleAmountOfImpairmentLoss
12600000
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.016 pure
CY2011 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y10M24D
CY2011 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
112942000 shares
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-113742000
CY2011 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.19
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.638 pure
CY2011 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21327000 shares
CY2011 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4530000
CY2011 us-gaap Revenues
Revenues
71480000
CY2011 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-136049000
CY2011 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
957000
CY2011 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
695371000
CY2011 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
24864000
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
2920000
CY2011 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1044000
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-135880000
CY2011 us-gaap Investment Income Interest
InvestmentIncomeInterest
2244000
CY2011 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1359000
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-123937000
CY2011 us-gaap Available For Sale Securities Gross Realized Gains Losses Sale Proceeds
AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds
210100000
CY2011 us-gaap Interest Paid
InterestPaid
10277000
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-132960000
CY2011 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-20164000
CY2011 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9023000
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-133978000
CY2011 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1978000
CY2011 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5390000
CY2011 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2071000
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18885000
CY2011 us-gaap Royalty Revenue
RoyaltyRevenue
10327000
CY2011 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss
-783000
CY2011 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
893000
CY2011 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
219783000
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9722000
CY2011 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
CY2011 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
CY2011 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
900000
CY2011 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
617000
CY2011 us-gaap Costs And Expenses
CostsAndExpenses
195417000
CY2011 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
CY2011 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
3555000
CY2011 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
46760000
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
222335000
CY2011 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
48959000
CY2011 us-gaap Cost Of Goods Sold
CostOfGoodsSold
21891000
CY2011 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
96000
CY2011 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-17516000
CY2011 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
1288000
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
18885000
CY2011 us-gaap Depreciation And Amortization
DepreciationAndAmortization
14951000
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2443000
CY2011 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1000
CY2011 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
210089000
CY2011 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1013000
CY2011 us-gaap Interest Expense
InterestExpense
10223000
CY2011 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
1000
CY2011 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3384000
CY2011 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
219783000
CY2011 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-46536000
CY2011 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-111952000
CY2011 us-gaap Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
CY2013 dei Entity Registrant Name
EntityRegistrantName
NEKTAR THERAPEUTICS
CY2011 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
921000
CY2011 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
96000
CY2011 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-129000
CY2011 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2400000
CY2011 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
383052000
CY2011 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
1800000
CY2011 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-384000
CY2011 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1018000
CY2011 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
916000
CY2011 nktr Increase Decrease In Accrued Clinical Trial Expenses
IncreaseDecreaseInAccruedClinicalTrialExpenses
-191000
CY2011 nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
36289000
CY2011 nktr Depreciation Expense And Amortization Of Leased Assets
DepreciationExpenseAndAmortizationOfLeasedAssets
15000000
CY2013 dei Trading Symbol
TradingSymbol
NKTR
CY2013 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2013 dei Amendment Flag
AmendmentFlag
false
CY2013 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2013 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013 dei Document Type
DocumentType
10-K
CY2013 dei Document Period End Date
DocumentPeriodEndDate
2013-12-31
CY2013 dei Entity Central Index Key
EntityCentralIndexKey
0000906709
CY2013 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2013 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2013 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.009 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35 pure
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y2M12D
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
115732000 shares
CY2013 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
32000
CY2013 nktr Percentage Of Accounts Receivable Customers Three
PercentageOfAccountsReceivableCustomersThree
0.28 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38527000
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.40
CY2013 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M12D
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.612 pure
CY2013 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss
-268000
CY2013 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
6273000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4091000
CY2013 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12959000 shares
CY2013 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
8208000
CY2013 us-gaap Revenues
Revenues
148921000
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-162837000
CY2013 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1014000
CY2013 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
268068000
CY2013 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
44846000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
1300000
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
392000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-161068000
CY2013 us-gaap Investment Income Interest
InvestmentIncomeInterest
732000
CY2013 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-6423000
CY2013 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-664000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-120130000
CY2013 us-gaap Available For Sale Securities Gross Realized Gains Losses Sale Proceeds
AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds
2900000
CY2013 us-gaap Interest Paid
InterestPaid
17590000
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
51800000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-159768000
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3576000
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-39638000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-162013000
CY2013 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
2992000
CY2013 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-4817000
CY2013 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-824000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17708000
CY2013 us-gaap Royalty Revenue
RoyaltyRevenue
1148000
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-12399000
CY2013 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
1026000
CY2013 nktr Noncash Interest Expense On Liability From Sale Of Royalties
NoncashInterestExpenseOnLiabilityFromSaleOfRoyalties
22309000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
17708000
CY2013 nktr Debt Instrument Maximum Maturity Period
DebtInstrumentMaximumMaturityPeriod
Two years or less
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
14275000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
13630000
CY2013 nktr Severance Payment Period For Employees
SeverancePaymentPeriodForEmployees
6 months
CY2013 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
CY2013 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1000000
CY2013 us-gaap Costs And Expenses
CostsAndExpenses
269051000
CY2013 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
CY2013 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
5481000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
40532000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2216000
CY2013 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
55042000
CY2013 us-gaap Cost Of Goods Sold
CostOfGoodsSold
38509000
CY2013 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
406000
CY2013 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1000
CY2013 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
2887000
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1915000
CY2013 us-gaap Interest Expense
InterestExpense
18453000
CY2013 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
50000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6199000
CY2013 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-55919000
CY2013 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
422000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
49909000
CY2013 us-gaap Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss
AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss
-470000
CY2013 us-gaap Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
190010000
CY2013 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
7808000
CY2013 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
9164000
CY2013 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
49000
CY2013 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
8208000
CY2013 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2013 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
CY2013 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1839000
CY2013 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
1838000
CY2013 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-65000
CY2013 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-20000
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2900000
CY2013 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
319181000
CY2013 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
4100000
CY2013 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-166000
CY2013 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
1557000
CY2013 nktr Increase In Noncash Royalty Revenue Based On Estimates Of Net Sales
IncreaseInNoncashRoyaltyRevenueBasedOnEstimatesOfNetSales
4600000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.009 pure
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2013 nktr Discount Rate Used To Determine Present Value Of Litigation Settlement
DiscountRateUsedToDeterminePresentValueOfLitigationSettlement
0.08 pure
CY2013 nktr Restricted Stock Units Award Depletion Ratio
RestrictedStockUnitsAwardDepletionRatio
1:1.5
CY2013 nktr Maximum Contribution Per Employee Annual Salary Percentage
MaximumContributionPerEmployeeAnnualSalaryPercentage
0.60 pure
CY2013 nktr Sublease Term Commenced End Date
SubleaseTermCommencedEndDate
January 31, 2020
CY2013 nktr Increase Decrease In Accrued Clinical Trial Expenses
IncreaseDecreaseInAccruedClinicalTrialExpenses
-595000
CY2013 nktr Number Of Components Within Business Segment
NumberOfComponentsWithinBusinessSegment
2 Segment
CY2013 nktr Number Of Reporting Units To Evaluate Goodwill For Impairment
NumberOfReportingUnitsToEvaluateGoodwillForImpairment
1 Reporting_Unit
CY2013 nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
80872000
CY2013 nktr Maturity Term Of Investments Considered As Short Term
MaturityTermOfInvestmentsConsideredAsShortTerm
Less than one year
CY2013 nktr Federal Orphan Drug Credits
FederalOrphanDrugCredits
17700000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
2809000
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
983000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-174258000
CY2012 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
4500000
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
114820000 shares
CY2013 nktr Number Of Operating Business Segment
NumberOfOperatingBusinessSegment
1 Segment
CY2013 nktr Valuation Allowance Related To Stock Based Compensation And Exercises
ValuationAllowanceRelatedToStockBasedCompensationAndExercises
35600000
CY2012 us-gaap Investment Income Interest
InvestmentIncomeInterest
2315000
CY2013 nktr Sublease Term Commenced Start Date
SubleaseTermCommencedStartDate
August 2010
CY2013 nktr Cash Severance Payment For To Chief Executive Officer
CashSeverancePaymentForToChiefExecutiveOfficer
24 months base salary plus annual target incentive pay
CY2013 nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
22055000
CY2013 nktr Redemption Price As Percentage Of Principal Amount In Case Of Change Of Control
RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfChangeOfControl
1.01 pure
CY2013 nktr Debt Instrument Weighted Average Maturity Period One
DebtInstrumentWeightedAverageMaturityPeriodOne
One year or less
CY2013 nktr Unrecognized Tax Benefits Period Increase Decrease Reasonable Period Of Change
UnrecognizedTaxBenefitsPeriodIncreaseDecreaseReasonablePeriodOfChange
Next twelve months
CY2013 nktr Percentage Of Amount Realized Upon Ultimate Settlement
PercentageOfAmountRealizedUponUltimateSettlement
0.50 pure
CY2013 nktr Severance Payment Period For Executives
SeverancePaymentPeriodForExecutives
12 months
CY2013 nktr Percentage Of Accounts Receivable Customers One
PercentageOfAccountsReceivableCustomersOne
0.30 pure
CY2013 nktr Percentage Of Accounts Receivable Customers Two
PercentageOfAccountsReceivableCustomersTwo
0.28 pure
CY2013 nktr Sublease Term Commenced Period
SubleaseTermCommencedPeriod
114 months
CY2012 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-6031000
CY2013 nktr Percentage Ceiling On Rent Increase
PercentageCeilingOnRentIncrease
0.03 pure
CY2013 nktr Capital Leases Termination Date
CapitalLeasesTerminationDate
2016-10-05
CY2013 nktr Maturity Term Of Investments In Marketable Securities To Be Considered As Cash Equivalents
MaturityTermOfInvestmentsInMarketableSecuritiesToBeConsideredAsCashEquivalents
Three months
CY2013 nktr Convertible Subordinated Notes Maturity Date
ConvertibleSubordinatedNotesMaturityDate
2012-09-28
CY2013 nktr Noncash Interest Expense
NoncashInterestExpense
22309000
CY2013 nktr Redemption Price As Percentage Of Principal Amount In Case Of Sale Of Assets
RedemptionPriceAsPercentageOfPrincipalAmountInCaseOfSaleOfAssets
1.00 pure
CY2013 nktr Estimated Annual Interest Rate On Royalty Liability
EstimatedAnnualInterestRateOnRoyaltyLiability
0.17 pure
CY2013 nktr Repayment Of And Proceeds From Sale Of Future Royalties Net Of Transaction Costs
RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts
-3000000
CY2013 nktr Increase Decrease In Milestone Payment Liabilities
IncreaseDecreaseInMilestonePaymentLiabilities
70000000
CY2013 nktr Federal Orphan Drug Credits Expiration Year
FederalOrphanDrugCreditsExpirationYear
2026
CY2013 nktr Sublease Term Commenced Start Date Amendment
SubleaseTermCommencedStartDateAmendment
December 28, 2011
CY2013 nktr Sublease Term Commenced End Date Amendment
SubleaseTermCommencedEndDateAmendment
January 31, 2020
CY2013 nktr Litigation Settlement Payment Description
LitigationSettlementPaymentDescription
August 1, 2007, between us (and our subsidiaries) and Bayer Healthcare LLC, as amended, related to the inhaled amikacin program in exchange for (i) a $5.0 million payment due on April 1, 2014; (ii) a $5.0 million payment due on January 1, 2015, (iii) a series of four $500,000 payments each due on April 1, 2014, January 1, 2015, January 1, 2016, and January 1, 2017, respectively; and (iv) certain other terms and conditions.
CY2013 nktr Depreciation Expense And Amortization Of Leased Assets
DepreciationExpenseAndAmortizationOfLeasedAssets
13000000
CY2013 nktr Partial Repayment Of Royalty Sale Proceeds
PartialRepaymentOfRoyaltySaleProceeds
3000000
CY2013 nktr Potential Development Milestones
PotentialDevelopmentMilestones
144300000
CY2012 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1021000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-45106000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-55063000
CY2012 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
164662000
CY2013Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
11661000
CY2012 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
35399000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26801000
CY2012 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
47349000
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-129756000
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.50
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.622 pure
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13970000 shares
CY2012 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4117000
CY2012 us-gaap Revenues
Revenues
81191000
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-171109000
CY2012 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-845000
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-141201000
CY2012 us-gaap Available For Sale Securities Gross Realized Gains Losses Sale Proceeds
AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds
5400000
CY2012 us-gaap Interest Paid
InterestPaid
9620000
CY2012 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
43600000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-171449000
CY2012 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
867000
CY2012 us-gaap Repayments Of Subordinated Debt
RepaymentsOfSubordinatedDebt
172407000
CY2012 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-30248000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-171855000
CY2012 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
2437000
CY2012 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5613000
CY2012 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
746000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16199000
CY2012 us-gaap Royalty Revenue
RoyaltyRevenue
4874000
CY2012 us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLoss
1206000
CY2012 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
591000
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10583000
CY2012 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
42548000
CY2012 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
25000000
CY2012 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1675000
CY2012 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
900000
CY2012 us-gaap Costs And Expenses
CostsAndExpenses
222392000
CY2012 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
CY2012 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-4034000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
41614000
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45618000
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2012Q1 us-gaap Revenues
Revenues
17949000
CY2012Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
6945000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
113020000
CY2012 us-gaap Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
CY2012 nktr Payment For Transaction Costs
PaymentForTransactionCosts
4400000
CY2012 nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
30127000
CY2012 nktr Valuation Allowance Related To Stock Based Compensation And Exercises
ValuationAllowanceRelatedToStockBasedCompensationAndExercises
35600000
CY2012 nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
10791000
CY2012 us-gaap Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss
AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss
470000
CY2012 us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
77940000
CY2012 us-gaap Cost Of Goods Sold
CostOfGoodsSold
30428000
CY2012 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-487000
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-9384000
CY2012 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
-10000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
16199000
CY2012 us-gaap Depreciation And Amortization
DepreciationAndAmortization
14508000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
10125000
CY2012 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1000
CY2012 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
5378000
CY2012 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1495000
CY2012 us-gaap Interest Expense
InterestExpense
15489000
CY2012 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-48000
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-122000
CY2012 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-60007000
CY2012 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-422000
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
148675000
CY2012 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
6320000
CY2012 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
3275000
CY2012 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-49000
CY2012 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
4117000
CY2012 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2012 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
CY2012 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
893000
CY2012 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
1029000
CY2012 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-16000
CY2012 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-227000
CY2012 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2800000
CY2012 us-gaap Income Tax Reconciliation Tax Settlements Foreign
IncomeTaxReconciliationTaxSettlementsForeign
6510000
CY2012 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
307887000
CY2012 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
137000
CY2012 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-137000
CY2012 us-gaap Direct Operating Cost Royalty Expense
DirectOperatingCostRoyaltyExpense
2900000
CY2012 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
5278000
CY2012 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
1100000
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
406000
CY2012 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
60000
CY2012 nktr Percentage Of Accounts Receivable Customers Three
PercentageOfAccountsReceivableCustomersThree
0.14 pure
CY2012 nktr Increase Decrease In Accrued Clinical Trial Expenses
IncreaseDecreaseInAccruedClinicalTrialExpenses
5547000
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-43547000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43914000
CY2012Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
7228000
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34016000
CY2012 nktr Percentage Of Accounts Receivable Customers Four
PercentageOfAccountsReceivableCustomersFour
0.11 pure
CY2012 nktr Percentage Of Accounts Receivable Customers One
PercentageOfAccountsReceivableCustomersOne
0.38 pure
CY2012 nktr Percentage Of Accounts Receivable Customers Two
PercentageOfAccountsReceivableCustomersTwo
0.27 pure
CY2012 nktr Noncash Interest Expense
NoncashInterestExpense
18057000
CY2012 nktr Repayment Of And Proceeds From Sale Of Future Royalties Net Of Transaction Costs
RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts
119588000
CY2012 nktr Depreciation Expense And Amortization Of Leased Assets
DepreciationExpenseAndAmortizationOfLeasedAssets
13800000
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2013Q3 us-gaap Revenues
Revenues
60909000
nktr Noncash Interest Expense On Liability From Sale Of Royalties
NoncashInterestExpenseOnLiabilityFromSaleOfRoyalties
40366000
nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
32846000
nktr Proceeds From Sale Of Potential Future Royalties
ProceedsFromSaleOfPotentialFutureRoyalties
124000000
CY2013Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
14672000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6525000
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-37932000
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-41097000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-16543000
CY2013Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
12877000
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33201000
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
nktr Partial Repayment Of Royalty Sale Proceeds
PartialRepaymentOfRoyaltySaleProceeds
3000000
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2013Q2 us-gaap Revenues
Revenues
33862000
CY2013Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
10324000
CY2013Q1 us-gaap Revenues
Revenues
23004000
CY2013Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
11810000
CY2012Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
8707000
CY2012Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35085000
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
CY2012Q2 us-gaap Revenues
Revenues
23684000
CY2012Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
9694000
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-26988000
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-34285000
CY2012Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
7203000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-32605000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-42748000
CY2013Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
5011000
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
52230000
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2012Q3 us-gaap Revenues
Revenues
18412000
CY2012Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
8355000
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-32900000
CY2012Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.46
CY2012Q4 us-gaap Revenues
Revenues
21146000
CY2012Q4 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
10405000
CY2012Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-43381000
CY2012Q4 us-gaap Net Income Loss
NetIncomeLoss
-52926000
CY2012Q4 us-gaap Cost Of Goods Sold
CostOfGoodsSold
7290000
CY2012Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46373000
CY2013Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2013Q4 us-gaap Revenues
Revenues
31146000
CY2013Q4 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
8040000
CY2013Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-35894000
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
-47659000
CY2013Q4 us-gaap Cost Of Goods Sold
CostOfGoodsSold
8960000
CY2013Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48248000

Files In Submission

Name View Source Status
0001193125-14-073093-index-headers.html Edgar Link pending
0001193125-14-073093-index.html Edgar Link pending
0001193125-14-073093.txt Edgar Link pending
0001193125-14-073093-xbrl.zip Edgar Link pending
d646233d10k.htm Edgar Link pending
d646233dex1028.htm Edgar Link pending
d646233dex1029.htm Edgar Link pending
d646233dex211.htm Edgar Link pending
d646233dex231.htm Edgar Link pending
d646233dex311.htm Edgar Link pending
d646233dex312.htm Edgar Link pending
d646233dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g64623301.jpg Edgar Link pending
g646233g16f09.jpg Edgar Link pending
nktr-20131231.xml Edgar Link completed
nktr-20131231.xsd Edgar Link pending
nktr-20131231_cal.xml Edgar Link unprocessable
nktr-20131231_def.xml Edgar Link unprocessable
nktr-20131231_lab.xml Edgar Link unprocessable
nktr-20131231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending